ASLAN's Downsized US IPO Off To A Slump Start
Executive Summary
Singapore venture ASLAN's US IPO has got off to a disappointing start, with the shares in what was already a downsized offering falling sharply in early trading.
You may also be interested in...
ASLAN Cuts Costs, Jobs And Refocuses After Varlitinib Setback
Singapore-based company prioritizes resources and cuts jobs following the recent Phase II failure of its lead pipeline asset in first-line gastric cancer.
Hong Kong Ushers in 'New Era' For Bioventures As Listing Rules Eased
The introduction of new listing rules in Hong Kong makes it easier for biotech companies to go public and provides incentives for both China-based and international companies to float there rather than in New York or elsewhere, although some concerns linger.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.